The vaccine industry, particularly, in major Western markets, continues to be dominated by a few major, long-established players
that primarily manufacture aging, long-marketed, non-recombinant (nongenetically engineered) vaccines. The industry, however,
will be changing in the coming years and this change may come rather rapidly. According to BioPlan's recently released analysis
of 10-year industry trends (1), a confluence of technological advances in bioprocessing is making vaccine manufacture cheaper,
faster, and simpler. These advances include:
- Single-use systems (SUS)/disposable bioprocessing systems
- Modular/transportable bioprocessing facilities
- Novel expression systems/improved cell lines
- New purification technologies.
As these technologies advance and are increasingly adopted for commercial-scale manufacturing, the industry will see an evolution
in vaccine manufacture. Significant improvements are now commonly being reported as companies develop, adopt, and adapt bioprocessing
technologies to vaccine manufacture.
Ronald A. Rader
Single use adoption
BioPlan's 10th Annual Report documents increasing adoption of these technologies and their impact on biopharmaceutical manufacturers.
Survey data show that bioprocessing at pre-commercial scales, such as manufacture for clinical trials, is now thoroughly dominated
by SUS (i.e., disposables) use. This increase included 78% of those surveyed reporting current use of SUS bioreactors and
92% using SUS filter cartridges at some level in bioprocessing (see Figure 1).
SUS have moved into large-scale vaccines manufacture more slowly, partly due to the demands for large-scale equipment. In
the BioPlan study, vendors were asked if they provide sufficiently scalable single-use disposables and techniques. Overall,
53% of the industry considers scale to be a significant adoption restriction. And vaccine manufacturers place inability to
scale up SUS devices high on the list of concerns. SUS involve one-time use of bioprocessing equipment composed of plastics,
not traditional stainless steel. SUS allow flexible manufacture when, and at the scale needed, with substantial reductions
in costs and time, including presterilized equipment. In contrast, stainless-steel bioreactor-anchored facilities require
costly and complex infrastructure, which further includes complex piping, including steam used for sterilizing stainless-steel
equipment so it may be reused, which adds weeks to batch turnaround time.
Figure 1: Selected single-use applications in biomanufacturing. (FIGURE 1 IS COURTESY OF THE AUTHOR)
Currently, SUS bioreactors top out at 2000 L, with many engineering challenges (e.g., weight) when larger. Where this does
not provide sufficient manufacturing capacity, multiple parallel SUS process lines can be implemented. With advancing SUS
technology, better plastics and new designs are being developed using SUS (vs. stainless steel) for their application in precommercial
R&D, clinical-trial-material supply, and commercial manufacture. This use of SUS is projected to result in the market (primarily
US and EU) for SUS equipment at a commercial scale growing 1000% in five years to $1.5 billion/year (2).